At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 13 enrolled
Drug / intervention
sunitinib malatedrug
Likely dose
sunitinib malate 37.5 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase II Trial of Sunitinib (SU11248) in Multiple Myeloma
In Brief
A Phase 2 clinical trial evaluating sunitinib malate for Refractory Multiple Myeloma and 3 related conditions. Completed, enrolled 13 participants across 1 site.
Detailed Summary
This phase II trial is studying how well sunitinib works in treating patients with relapsed multiple myeloma. Sunitinib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the cancer
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsRefractory Multiple Myeloma, Stage I Multiple Myeloma, Stage II Multiple Myeloma, Stage III Multiple Myeloma
CountriesUnited States
Collaborators--
Timeline
Phase 2CompletedFinished
20082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedAug 2007
Enrollment StartSep 2007
Primary CompletionMar 2009
Study CompletionAug 2010
TodayJul 2026
First PostedAug 9, 2007
Enrollment StartSep 1, 2007
Primary CompletionMar 1, 2009
Study CompletionAug 1, 2010
TodayJul 2, 2026
Enrollment to primary: 1.5 yearsPosted 18.9 years ago
Interventions
sunitinib malatedrug
Oral 37.5 mg each day of the 6-week cycle (continuous dosing).